irinotecan fresenius 20 mg/ml concentrado para solucion para perfusion efg
fresenius kabi espaÑa, s.a.u. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 15 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán
irinotecan sandoz 20 mg/ml concentrado para solucion para perfusion efg
sandoz farmaceutica s.a. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 25 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán
irinotecan hikma 20 mg/ml concentrado para solucion para perfusion efg
hikma farmaceutica (portugal) s.a. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 25 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán
irinotecan aurovitas 20 mg/ml concentrado para solucion para perfusion
eugia pharma (malta) limited - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 25 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán
irinotecan baxter irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial
baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; water for injections; hydrochloric acid; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan baxter irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial
baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan baxter irinotecan hydrochloride trihydrate 300 mg/15 ml concentrated injection vial
baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; hydrochloric acid; sodium hydroxide; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan combino pharm 20 mg/ml concentrado para solucion para perfusion
combino pharm, s.l. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 5 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán
irinotecan kewl 20 mg/ml concentrado para solucion para perfusion efg
gp-pharm, s.a. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 25 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán
irinotecan qilu 20 mg/ml concentrado para solucion para perfusion efg
qilu pharma spain s.l. - irinotecan hidrocloruro trihidrato - concentrado para soluciÓn para perfusiÓn - 20 mg/ml inyectable 25 ml - irinotecan hidrocloruro trihidrato 20 mg - irinotecán